* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Sections 11 to 17
Survey
Document related concepts
Transcript
WHO Model List of Essential Drugs (EDL) with rational and evidence where available 11th edition (Nov. 1999) By Therapeutic Group 11. BLOOD PRODUCTS AND PLASMA SUBSTITUTES 11.1 Plasma substitutes *dextran 70 injectable solution, 6% EDL2 Replaced dextran 40. To increase plasma volume Cochrane Library: One review on crystalloids and colloids *polygeline injectable solution, 3.5% EDL6 Advantages over dextran-only one plasma substitute is necessary Cochrane Library: One review on crystalloids and colloids 11.2 Plasma fractions for specific use All plasma fractions should comply with the WHO Requirements for the Collection, Processing and Quality Control of Blood, Blood Components, and Plasma Derivatives (Revised 1992). WHO Technical Report Series, No. 840, 1994, Annex 2. Albumin removed EDL 11 Complementary drugs *factor VIII concentrate (C) (2, 8) (dried) For specific coagulation disorders *factor IX complex concentrate (coagulation factors, II, VII, IX, X) (C) (2, 8) (dried) For specific coagulation disorders tablet, 50 mg, 100 mg EDL7 Cardioselective Badrenoreceptor antagonists (Beta blocker) advantageous in some patients Cochrane Library: Number of reviews For acute treatment of angina Tablets have limited shelf life 12. CARDIOVASCULAR DRUGS 12.1 Antianginal drugs *atenolol glyceryl trinitrate tablet (sublingual), 500 micrograms Section 2 Page 1 of 13 CE6 Strong evidence of effect especially in those at greatest risk of death after an MI WHO Model List of Essential Drugs (EDL) with rational and evidence where available 11th edition (Nov. 1999) By Therapeutic Group Cochrane Library: No reviews but RCTs exist *isosorbide dinitrate *verapamil (10) tablet (sublingual), 5 mg For treatment of angina CE6 Insufficient evidence of effect in unstable angina on rates of death or MI tablet, 40 mg, 80 mg (hydrochloride) EDL8 Added replaces nifedipine for angina. For treatment of angina Cochrane Library: One review in pregnancy and RCTs exist tablet, 50 mg, 100 mg EDL7 Beta blocker Variety of uses especially SVT and post myocardial infarct Cochrane Library: Number of reviews tablet, 62.5 micrograms, 250 micrograms; oral solution 50 micrograms; injection 250 micrograms/ml in 2-ml ampoule EDL10 Antiarrhythmic Major cause of ADRs Variety of uses especially heart failure and AF CE6 Digoxin is no better than placebo at restoring sinus rhythm in acute AF but lowers ventricular rate in the short term injection, 20 mg (hydrochloride)/ml in 5-ml ampoule Ventricular arythmias especially after myocardial infarct. First line emergency use. Cochrane Library: No reviews or RCTs found tablet, 40 mg, 80 mg (hydrochloride); injection, 2.5 mg (hydrochloride)/ml in 2-ml ampoule Used for SVTs usually by injection followed by oral use. Cochrane Library: No reviews but RCTs exist 12.2 Antiarrhythmic drugs *atenolol digoxin (4, 11) lidocaine verapamil (8, 10) Complementary drugs Section 2 Page 2 of 13 CE6 verapamil is no better than placebo at restoring sinus rhythm in acute AF but lowers ventricular rate in the short term WHO Model List of Essential Drugs (EDL) with rational and evidence where available 11th edition (Nov. 1999) By Therapeutic Group epinephrine (adrenaline) (C) injection 1 mg (as hydrochloride) in 1-ml ampoule Used in cardio-pulmonary resuscitation Cochrane Library: One review and RCTs exist isoprenaline (C) injection, 20 micrograms (hydrochloride)/ml EDL8 For emergency treatment of bradycardia Cochrane Library: No reviews but RCTs exist *procainamide (B) tablet, 250 mg, 500 mg (hydrochloride); injection, 100 mg (hydrochloride)/ml in 10ml ampoule For ventricular arythmias especially after myocardial infarct Cochrane Library: No reviews but RCTs exist *quinidine (A) (7) tablet, 200 mg (sulfate) Suppression of SVTs and ventricular arythmias Cochrane Library: No reviews but RCTs exist tablet, 50 mg, 100 mg Beta blocker Variety of uses including hypertension Cochrane Library: Number of reviews ACE inhibitor for essential hypertension. Also used in combination with thiazide diuretics Cochrane Library: Number of reviews 12.3 Antihypertensive drugs *atenolol *captopril scored tablet, 25 mg CE6 Two SRs show reduction in mortality and morbidity with minimal side effects CE6 Two SRs show reduction in mortality and morbidity with minimal side effects *hydralazine tablet, 25 mg, 50 mg (hydrochloride); powder for injection, 20 mg (hydrochloride) in ampoule Used with other agents for moderate to severe hypertension CE6 effective in reducing serious hypertension in pregnancy *hydrochlorothiazide scored tablet, 25 mg Thiazide diuretic. First line antihypertensive treatment CE6 Two SRs show reduction in mortality and morbidity with minimal side effects Section 2 Page 3 of 13 WHO Model List of Essential Drugs (EDL) with rational and evidence where available 11th edition (Nov. 1999) By Therapeutic Group methyldopa (7) tablet, 250 mg Centrally acting antihypertensive Cochrane Library: Number of reviews *nifedipine (10) sustained release formulations, tablet 10 mg Relaxes vascular smooth muscle and dilates coronary and peripheral arteries CE6 Calcium channel blocker given in first few days post MI do not reduce deaths but may increase death in those with reduced left ventricular function Calcium channel blocker *reserpine tablet, 100 micrograms, 250 micrograms; injection, 1 mg in 1-ml ampoule Antihypertensive that reduces catecholamines both peripherally and centrally Cochrane Library: One review in the elderly Complementary drugs *prazosin (B) tablet, 500 micrograms, 1 mg EDL11 Replaces doxazosin as Aadrenoreceptor antagonist, less expensive Cochrane Library: One review in pregnancy and RCTs *sodium nitroprusside (C) (2, 8) powder for infusion, 50 mg in ampoule EDL2 For emergency use in hypertensive crises Cochrane Library: No reviews but RCTs exist scored tablet, 25 mg EDL10 New section-cardiac failure. ACE inhibitor. Cochrane Library: Number of reviews Cardiac glycoside. Major cause of ADRs 12.4 Drugs used in heart failure *captopril *digoxin (4, 11) (4, 11) tablet, 62.5 micrograms, 250 micrograms; oral solution, 50 micrograms/ml; injection, 250 micrograms/ml in 2-ml ampoule CE6 Two SRs and recent RCTs show Ace inhibitors reduce mortality, hospital admission and ischaemic effects in heart failure Cochrane Library: One review CE6 Evidence that digoxin reduces morbidity in heart failure Section 2 Page 4 of 13 WHO Model List of Essential Drugs (EDL) with rational and evidence where available 11th edition (Nov. 1999) By Therapeutic Group dopamine injection, 40 mg (hydrochloride)in 5-ml vial Cochrane Library: reviews exist *hydrochlorothiazide tablet, 25 mg, 50 mg Thiazide diuretic Cochrane Library: reviews exist tablet, 100 mg Low dose aspirin used to prevent platelet aggregation CE6 routine use is beneficial unless other contra-indications. 75mg is as effective as higher doses. Reduces mortality: one life saved for every 40 treated in acute MI. Also of value if started within 48 hours of acute ischaemic attack powder for injection, 100,000 IU, 750,000 IU in vial EDL7 For the Rx of patients a few hours after coronary thrombosis So called 'clot buster' CE6 Prompt treatment within 6 hrs and perhaps up to 12 hours reduces mortality in acute MI 12.5 Antithrombotic drugs acetylsalicylic acid Complementary drug streptokinase (C) 12.6 Lipid-lowering agents The WHO Expert Committee on Use of Essential Drugs recognizes the value of lipid-lowering drugs in treating patients with hyperlipidaemia. HMG-CoA reductase inhibitors, often referred to as "statins", are a family of potent and effective lipid-lowering drugs with a good tolerability profile. Several of these drugs have been shown to reduce the incidence of fatal and non-fatal myocardial infarction, stroke and mortality (all causes), as well as the need for coronary by-pass surgery . All remain very costly but may be cost effective for secondary prevention of cardiovascular disease as well as for primary prevention in some very high-risk patients. Since no single drug has been shown to be significantly more effective or less expensive than others in the group, none is included in the Model List; the choice of drug for use in patients at highest risk should be decided at the national level. 13. DERMATOLOGICAL DRUGS (topical) 13.1 Antifungal drugs Section 2 Page 5 of 13 WHO Model List of Essential Drugs (EDL) with rational and evidence where available 11th edition (Nov. 1999) By Therapeutic Group benzoic acid + salicylic acid ointment or cream, 6% + 3% Also known as Whitfields ointment. Used for ringworm Cochrane Library: one review of topical treatments for fungal infections *miconazole ointment or cream, 2% (nitrate) For candidal skin infections Cochrane Library: one review of topical treatments for fungal infections sodium thiosulfate solution, 15% EDL7 For pityriasis versicolor Cochrane Library: No reviews or RCTs detergent-based suspension, 2% EDL6 For the treatment of pityriasis versicolor and seborrhoeic dermatitis Cochrane Library: No reviews or RCTs aqueous solution, 0.5%; tincture, 0.5% EDL4 Considered at EDL 11 but felt benefits outweighed risks. Topical antiseptic Should be confined to use on unbroken skin Complementary drug selenium sulfide (C) 13.2 Anti-infective drugs *methylrosanilinium chloride (gentian violet) Cochrane Library: No reviews but RCTs exist neomycin sulfate + *bacitracin ointment, 5 mg + 500 IU bacitracin zinc/g Topical antibiotic ointment Cochrane Library: No reviews but RCTs exist *potassium permanganate aqueous solution 1:10 000 EDL9 Very inexpensive anti-infective agent. Main use in mycotic infections of the feet Cochrane Library: No reviews but one RCT silver sulfadiazine cream, 1%, in 500-g container EDL5 For treatment of burns. Topical antibiotic to treat and prevent infection Cochrane Library: No reviews but RCTs exist 13.3 Anti-inflammatory and antipruritic drugs Section 2 Page 6 of 13 WHO Model List of Essential Drugs (EDL) with rational and evidence where available 11th edition (Nov. 1999) By Therapeutic Group *betamethasone (3) ointment or cream, 0.1% (as valerate) Potent topical steroid Cochrane Library: No reviews but RCTs exist CE6 small short term RCTs over 1-4 weeks show improvement over placebo. *calamine lotion lotion For mild pruritus Effective ? Cochrane Library: No reviews or RCTs *hydrocortisone ointment or cream, 1% (acetate) Mild topical steroid Cochrane Library: No reviews but RCTs exist solution, 13% for dilution For exudative wounds and eczematous reactions. Final solution (0.65%) must be freshly prepared Dilute 5ml of 13% solution to 100ml for use. 13.4 Astringent drugs aluminium diacetate Cochrane Library: No reviews or RCTs exist 13.5 Drugs affecting skin differentiation and proliferation benzoyl peroxide lotion or cream, 5% EDL6 For treatment of acne Cochrane Library: No reviews but RCTs exist coal tar solution, 5% As an ingredient in topical ointments to treat psoriasis and possibly chronic atopic eczema. Cochrane Library: No reviews but RCTs exist Section 2 Page 7 of 13 WHO Model List of Essential Drugs (EDL) with rational and evidence where available 11th edition (Nov. 1999) By Therapeutic Group dithranol ointment, 0.1%-2% EDL5 For the treatment of psoriasis Cochrane Library: No reviews but RCTs exist CE6 evidence of effect in chronic plaque psoriasis for treatment and remission. fluorouracil ointment, 5% Cytotoxic for malignant and premalignant skin lesions. CE6 no evidence of effect in genital warts solution, 10-25% EDL4 added to main list. For anogenital warts. CE6 RCTs show podophyllum to be as effective as other treatments but less effective than surgical excision salicylic acid solution 5% EDL2 Effective, commonly used and inexpensive. For plantar warts Cochrane Library: one review of topical treatments for fungal infections urea ointment or cream, 10% EDL9 very inexpensive keratolytic agent without scientific evaluation Cochrane Library: No reviews but RCTs exist lotion, 25% Used to treat scabies Not recommended in children *podophyllum resin (7) 13.6 Scabicides and pediculicides *benzyl benzoate CE6 little evidence of effect- may be less than 50% cure rate permethrin cream 5%; lotion 1% EDL6 Replaces lindane, cheaper (lindane=gamma benzene hexachloride) For head lice and crab lice 13.7 Ultraviolet blocking agents Section 2 Page 8 of 13 CE6 effective in treatment of scabies with cure rates of up to 90% WHO Model List of Essential Drugs (EDL) with rational and evidence where available 11th edition (Nov. 1999) By Therapeutic Group Complementary drugs topical sun protection agent with activity against UVA and UVB (C) cream, lotion or gel EDL6 Skin protection especially people with xeroderma pigmentosa Cochrane Library: No reviews or RCTs found fluorescein eye drops, 1% (sodium salt) EDL2 Diagnostic agent in eye examination relating to superficial damage or a foreign body Cochrane Library: No reviews but RCTs exist *tropicamide eye drops, 0.5% EDL5 Short acting mydriatic for diagnostic ophthalmic procedures Cochrane Library: No reviews but RCTs exist 14. DIAGNOSTIC AGENTS 14.1 Ophthalmic drugs 14.2 Radiocontrast media CE6 less nephrotoxicity with low osmolality media amidotrizoate injection, 140-420 mg iodine (as sodium or meglumine salt)/ml in 20-ml ampoule Ionic contrast media barium sulfate aqueous suspension Contrast media for examination of the GI tract *iohexol injection 140 –350 mg iodine/ml in 5-ml, 10ml and 20-ml ampoule EDL11 Non ionic contrast media Safer than ionic contrast media Cochrane Library: No reviews but RCTs exist *iopanoic acid tablet, 500 mg Oral Ionic contrast media for cholecystography and cholangiography Cochrane Library: No reviews but RCTs exist *propyliodone oily suspension, 500-600 mg/ml in 20-ml ampoule (For administration only into the bronchial tree.) EDL4 For brochography. Can lead to dyspneoa and pneumonia EDL11 committee asked for review of this item Section 2 Page 9 of 13 Cochrane Library: No reviews but RCTs exist WHO Model List of Essential Drugs (EDL) with rational and evidence where available 11th edition (Nov. 1999) By Therapeutic Group Complementary drug *meglumine iotroxate (C) solution, 5-8 g iodine in 100-250 ml Ionic contrast media Cochrane Library: No reviews but RCTs exist EDL11 committee asked for review of this section 15. DISINFECTANTS AND ANTISEPTICS 15.1 Antiseptics *chlorhexidine solution, 5% ( digluconate) concentrate for dilution EDL2 Commonly used antiseptic *ethanol solution, 70% (denatured) EDL11 denatured added to prevent use as a beverage. Effective antiseptic for skin and hard surfaces Cochrane Library: No reviews but RCTs exist *polyvidone iodine solution, 10% EDL8 Replaced iodine Cochrane Library: No reviews but RCTs exist *chlorine base compound powder (0.1% available chlorine) for solution EDL7 name change EDL-10 originally calcium hypochlorite. Used in cleaning and disinfecting contaminated areas. Effective against HIV *chloroxylenol solution, 5% EDL10 Replaced phenolic disinfectants 15.2 Disinfectants Weak disinfectant glutaral solution, 2% EDL7Added as disinfectant 16. DIURETICS Section 2 Page 10 of 13 Now not favoured as unpleasant and toxic to use WHO Model List of Essential Drugs (EDL) with rational and evidence where available 11th edition (Nov. 1999) By Therapeutic Group *amiloride tablet, 5 mg (hydrochloride) EDL2An effective diuretic with potassium sparing properties Cochrane Library: No reviews but RCTs exist *furosemide tablet, 40 mg; injection, 10 mg/ml in 2-ml ampoule Potent loop diuretic Cochrane Library: No reviews but RCTs exist *hydrochlorothiazide tablet, 25 mg, 50 mg Thiazide diuretic Cochrane Library: No reviews but RCTs exist (8) tablet, 25 mg Potassium sparing diuretic potentiates action of loop and thiazide diuretics Cochrane Library: No reviews but RCTs exist (C) injectable solution, 10%, 20% Osmotic diuretic mainly used in cerebral oedema. CE6 no benefit in decreasing the risk of acute renal function compared to other fluids spironolactone (4, 7, 8) Complementary drug *mannitol 17. GASTROINTESTINAL DRUGS ED11 Committee asked for a revision of all drugs for peptic ulcer 17.1 Antacids and other antiulcer drugs aluminium hydroxide tablet, 500 mg; oral suspension, 320 mg/5 ml Antacid Cochrane Library: several reviews on dyspepsia *cimetidine tablet, 200 mg; injection, 200 mg in 2-ml ampoule EDL3 H2 antagonist reduces stomach acid. Used to treat stomach ulcers Cochrane Library: several reviews on dyspepsia CE6 Effective (SR) in relieving heartburn. Generally PPIs more effective magnesium hydroxide oral suspension, 550 mg equivalent to magnesium oxide/10 ml Acid and aperient Section 2 Page 11 of 13 Cochrane Library: several reviews on dyspepsia WHO Model List of Essential Drugs (EDL) with rational and evidence where available 11th edition (Nov. 1999) By Therapeutic Group 17.2 Antiemetic drugs metoclopramide tablet, 10 mg (hydrochloride); injection, 5 mg (hydrochloride)/ml in 2-ml ampoule EDL3 Anti-nauseant and antiemetic Cochrane Library: No reviews but RCTs exist *promethazine tablet, 10 mg, 25 mg (hydrochloride); elixir or syrup, 5 mg (hydrochloride)/5 ml; injection, 25 mg (hydrochloride)/ml in 2-ml ampoule Antihistamine for nausea, vertigo, motion sickness. Cochrane Library: No reviews but RCTs exist ointment or suppository Many proprietary preparations. Local soothing action. 17.3 Antihaemorrhoidal drugs *local anaesthetic, astringent and antiinflammatory drug 17.4 Anti-inflammatory drugs *hydrocortisone (B) suppository 25 mg (acetate); *retention enema For ulcerative colitis, proctitis Cochrane Library: several reviews *sulfasalazine (2) tablet, 500 mg; suppository 500 mg; retention enema For ulcerative colitis and maintenance and remission of active Crohns disease Cochrane Library: several reviews tablet, 0.6 mg (sulfate); injection, 1 mg (sulfate) in 1-ml ampoule For relief of smooth muscle spasm such as in irritable bowel and diverticular disease tablet, 7.5 mg (sennosides) (or traditional dosage forms) Stimulant laxative 17.5 Antispasmodic drugs *atropine 17.6 Laxatives *senna 17.7 Drugs used in diarrhoea Section 2 Page 12 of 13 Cochrane Library: several reviews WHO Model List of Essential Drugs (EDL) with rational and evidence where available 11th edition (Nov. 1999) By Therapeutic Group 17.7.1 Oral rehydration oral rehydration salts (for glucose-electrolyte solution) powder, 27.9 g/l; Components to reconstitute 1 litre of glucose-electrolyte solution: ORS Replaces fluid and salts lost in acute diarrhoea EDL11 committee asked for review of this section sodium chloride 3.5 g/l; trisodium citrate dihydrate* 2.9 g/l; potassium chloride 1.5 g/l; CE6 Number of RCTs looking at different formulations. One SR suggests rice based ORS reduces the 24 hour stool volume glucose, anhydrous 20.0 g/l *Trisodium citrate dihydrate may be replaced by sodium bicarbonate (sodium hydrogen carbonate) 2.5g/l. However, as the stability of this latter formulation is very poor under tropical conditions, it is only recommended when manufactured for immediate use. 17.7.2 Antidiarrhoeal (symptomatic) drugs *codeine (1a) tablet, 30 mg (phosphate) Opiate that reduces gut motility Section 2 Page 13 of 13 Cochrane Library: No reviews or protocols